CANC Among Its Peers
End-of-day Nov 18, 2026 · 1 ETFs by 1W
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | −1.7% | −8.1% | −6.6% | −11.7% | +11.9% | +15.8% | +81.7% | — | — | +64.2% |
| S&P 500 · VOO | −0.3% | −3.9% | −5.0% | −4.0% | +8.0% | +10.9% | +72.4% | +68.9% | +302.1% | — |
$61 of every $1,000 in CANC is Genmab
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S | Healthcare | 6.10% | $610.06 | 239K | $12.4M |
| 2 | LLYELI Lilly | Healthcare | 5.71% | $571.23 | 8,222 | $11.6M |
| 3 | RVMDRevolution Medicines | Healthcare | 5.23% | $522.80 | 65K | $10.7M |
| 4 | MRKMerck | Healthcare | 5.06% | $506.35 | 72K | $10.3M |
| 5 | ONCBeone Medicines | Healthcare | 4.46% | $446.47 | 22K | $9.1M |
| 6 | COGTCogent Biosciences | Healthcare | 4.35% | $435.43 | 319K | $8.9M |
| 7 | NOVN.SWNovartis AG | Healthcare | 4.32% | $431.90 | 55K | $8.8M |
| 8 | EXELExelixis | Healthcare | 3.85% | $385.27 | 115K | $7.8M |
| 9 | ABBVAbbvie | Healthcare | 3.49% | $348.79 | 24K | $7.1M |
| 10 | RHHBYRoche AG | Healthcare | 3.33% | $333.09 | 113K | $6.8M |
| 11 | BBIOBridgebio Pharma | Healthcare | 3.26% | $325.76 | 86K | $6.6M |
| 12 | CGONCG Oncology | Healthcare | 3.18% | $317.59 | 82K | $6.5M |
| 13 | HALOHalozyme Therapeutics | Healthcare | 3.00% | $299.67 | 64K | $6.1M |
| 14 | BMYBristol-myers Squibb | Healthcare | 2.79% | $279.37 | 93K | $5.7M |
| 15 | ELVNEnliven Therapeutics | Healthcare | 2.75% | $274.97 | 120K | $5.6M |
CANC has no close peers in our data yet: […]
No peers with a full year of prices to rank against yet.
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S | 6.10% |
| 2 | LLY | ELI Lilly & | 5.71% |
| 3 | RVMD | Revolution Medicines | 5.23% |
| 4 | MRK | Merck & | 5.06% |
| 5 | ONC | Beone Medicines | 4.46% |
| 6 | COGT | Cogent Biosciences | 4.35% |
| 7 | NOVN.SW | Novartis AG | 4.32% |
| 8 | EXEL | Exelixis | 3.85% |
| 9 | ABBV | Abbvie | 3.49% |
| 10 | RHHBY | Roche AG | 3.33% |
| Fund | Sharpe | Sortino | Volatility | Max DD | Beta | Fee / $10k |
|---|---|---|---|---|---|---|
| CANC | 0.61 | 0.92 | 24.3% | −14.1% | 0.81 | $99 |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 10, 2025 | Dec 11, 2025 | $0.0196 |
| Dec 11, 2024 | Dec 12, 2024 | $0.73 |
| Dec 13, 2023 | Dec 15, 2023 | $0.15 |